4 ms·
Author here. We’re bringing this technology to market. We’ve identified specific use cases where these methods can impact clinical decision making. Here’s our L
by jostmey 4y ago
Author here. We’re bringing this technology to market. We’ve identified specific use cases where these methods can impact clinical decision making. Here’s our LinkedIn page: https://www.linkedin.com/company/immunoscope https://www.linkedin.com/company/immunoscope . We’re looking to do our first raise
- ugh123 4y agoWhat studies, experiments, and/or trials has this gone through? Also, I see a list of "Publications" linked, but unsure how they relate to the work done here. "Diagnosing cancer by profiling the immune system" is a bold statement to make while merely linking to a github repo. The readme still leaves A LOT of questions
- arthur2e5 4y agoThe publications all appear to do what the README is describing, except for the part where the README says bugs are preventing some results from being reproduced. Going through the stuff chronologically seems to help understand how the ideas got put together. The 2017 MS paper is the oldest of the four and mentions a weaker MSPrecise method using summary statistics. I mean… if we really are sure some two things are somehow related, you might as well throw ML at it and see what it comes up. It's just linear, no super fancy models.